NASDAQ:EQ
Equillium Inc. Stock News
$1.56
+0.100 (+6.85%)
At Close: May 02, 2024
5 Stocks That More Than Doubled in Q1 With More Gains Ahead
10:56am, Monday, 01'st Apr 2024
Equillium (EQ), Laird Superfood (LSF), QuantaSing (QSG), Phunware (PHUN) and Arq (ARQ) more than double in the first quarter and are expected to continue their strong performances.
Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates
06:10pm, Monday, 25'th Mar 2024
Equillium, Inc. (EQ) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to earnings of $0.08 per share a year ago.
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis
5 Stocks That More Than Doubled in February
10:31am, Friday, 01'st Mar 2024
Janux Therapeutics (JANX), SoundHound (SOUN), ROOT, Equillium (EQ) and CleanSpark (CLSK) more than doubled in February.
5 Top-Ranked Stocks That Have More Than Doubled Year to Date
10:11am, Friday, 23'rd Feb 2024
Amid the broad-market rally, shares of Equillium (EQ), Phunware (PHUN), Super Micro Computer (SMCI), Vaxart (VXRT) and Dianthus Therapeutics (DNTH) have more than doubled this year.
Equillium to Present at the JonesTrading 2023 Healthcare Summit
08:00am, Monday, 02'nd Oct 2023
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis
Equillium, Inc. (EQ) Reports Q2 Loss, Tops Revenue Estimates
06:59pm, Wednesday, 09'th Aug 2023
Equillium, Inc. (EQ) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.41 per share a year ago.
Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
07:02pm, Thursday, 11'th May 2023
Equillium, Inc. (EQ) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.45 per share a year ago.
Equillium to Present at Two Upcoming Investor Conferences
08:00am, Tuesday, 08'th Nov 2022
LA JOLLA, Calif.
Why Is Equillium (EQ) Stock Soaring 20% Today?
02:20pm, Tuesday, 27'th Sep 2022
Clinical-stage biotechnology firm Equillium (NASDAQ: EQ ), which focuses on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, released encouraging clinical data rega
Equillium's stock is up 12% after sharing early data about its investigational lupus treatment
08:15am, Tuesday, 27'th Sep 2022
Shares of Equillium Inc. EQ, -3.98% gained 12.9% in premarket trading on Tuesday after the company shared a batch of interim data from an early stage trial evaluating its experimental treatment in 13
Equillium to Present at Two Upcoming Investor Conferences
08:00am, Wednesday, 31'st Aug 2022
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammato
Down 20.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Equillium, Inc. (EQ)
02:00pm, Tuesday, 29'th Mar 2022 Zacks Investment Research
Equillium, Inc. (EQ) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revi
Down 20.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Equillium, Inc. (EQ)
11:17am, Tuesday, 29'th Mar 2022
Equillium, Inc. (EQ) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revi
Equillium begins phase 3 trial of itolizumab for graft versus host disease
02:12pm, Friday, 04'th Mar 2022 Seeking Alpha
Equillium Inc (EQ) said it had begun a Phase 3 trial of its drug, itolizumab, in patients with acute graft-versus-host disease (aGVHD). aGVHD is an inflammatory response by the…
